{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:19:45Z","timestamp":1790961585262,"version":"4.1.0"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Faculty of Medicine, University of Bergen","award":["912065"],"award-info":[{"award-number":["912065"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Psoriasis is a chronic, inflammatory skin disease characterized by a dysregulated immune response and systemic inflammation. Up to one-third of patients with psoriasis have psoriatic arthritis (PsA). Targeted treatment with antibodies neutralizing tumor necrosis factor can ameliorate both diseases. We here explored the impact of long-term infliximab treatment on the composition and activity status of circulating immune cells involved in chronic skin and joint inflammation. Immune cells were analyzed by multicolor flow cytometry. We measured markers of immune activation in peripheral blood mononuclear cell populations in 24 infliximab-treated patients with psoriasis\/PsA compared to 32 healthy controls. We observed a significant decrease in the frequency of both peripheral natural killer (NK) cells and their subset CD56dimCD16+ NK cells in PsA compared to healthy controls and patients with psoriasis. The latter had a strong-positive correlation with psoriasis area severity index (PASI) in these patients, while CD56brightCD16\u2212 NK cells were negatively correlated with PASI. In addition, we observed an upregulation of CD69+ intermediate CD14+CD16+ and CD69+ classical CD14+CD16\u2212 monocytes in PsA and increased activity of CD38+ intermediate CD14+CD16+ monocytes in patients with psoriasis. Compared to healthy controls, psoriasis patients demonstrated shifts of the three B-cell subsets with a decrease in transitional CD27-CD38high B cells. Our exploratory study indicates a preserved pathophysiological process including continuous systemic inflammation despite clinical stability of the patients treated with infliximab.<\/jats:p>","DOI":"10.1093\/cei\/uxae070","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T21:28:29Z","timestamp":1723152509000},"page":"329-340","source":"Crossref","is-referenced-by-count":14,"title":["Immune cell activity during anti-TNF treatment in patients with psoriasis and psoriatic arthritis"],"prefix":"10.1093","volume":"218","author":[{"given":"Aleksandra","family":"Petrovic","sequence":"first","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Marie","family":"Samuelsen","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Davies","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders K","family":"Aarebrot","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Holmes","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brith","family":"Bergum","sequence":"additional","affiliation":[{"name":"Flow Cytometry Core Facility, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Jonsson","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene F","family":"Sandvik","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Haukeland University Hospital , Bergen ,","place":["Norway"]},{"name":"Department of Clinical Medicine, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje M","family":"Solberg","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]},{"name":"Department of Dermatology, Haukeland University Hospital , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2199-2315","authenticated-orcid":false,"given":"Silke","family":"Appel","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]},{"name":"Flow Cytometry Core Facility, Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"2024111301173590200_CIT0001","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"2024111301173590200_CIT0002","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"2024111301173590200_CIT0003","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2024111301173590200_CIT0004","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris","volume":"13","author":"Henseler","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"2024111301173590200_CIT0005","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.intimp.2015.11.005","article-title":"Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-\u03b1 treatment in psoriasis","volume":"29","author":"Luan","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"2024111301173590200_CIT0006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000330330","article-title":"Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response","volume":"223","author":"Quaglino","year":"2011","journal-title":"Dermatology"},{"key":"2024111301173590200_CIT0007","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N Engl J Med"},{"key":"2024111301173590200_CIT0008","first-page":"371","article-title":"Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab","volume":"179","author":"Aarebrot","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024111301173590200_CIT0009","first-page":"s216","article-title":"Psoriasis and psoriatic arthritis overview","volume":"22","author":"Menter","year":"2016","journal-title":"Am J Manag Care"},{"key":"2024111301173590200_CIT0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/ard.2010.132423","article-title":"A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis","volume":"70","author":"Finzel","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024111301173590200_CIT0011","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/jdv.16018","article-title":"Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study","volume":"34","author":"Rungapiromnan","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111301173590200_CIT0012","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2174\/1871530319666191008170409","article-title":"The association of metabolic syndrome and psoriasis: a systematic review and meta-analysis of observational study","volume":"20","author":"Choudhary","year":"2020","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2024111301173590200_CIT0013","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis - head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"key":"2024111301173590200_CIT0014","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2019.05.042","article-title":"Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis","volume":"73","author":"Yu","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2024111301173590200_CIT0015","doi-asserted-by":"crossref","first-page":"58338","DOI":"10.18632\/oncotarget.16873","article-title":"Inflammatory factor TNF-\u03b1 promotes the growth of breast cancer via the positive feedback loop of TNFR1\/NF-\u03baB (and\/or p38)\/p-STAT3\/HBXIP\/TNFR1","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"2024111301173590200_CIT0016","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1073\/pnas.86.7.2336","article-title":"Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B","volume":"86","author":"Osborn","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024111301173590200_CIT0017","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.0022-202X.2005.23735.x","article-title":"Differential expression of phosphorylated NF-kappaB\/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept","volume":"124","author":"Lizzul","year":"2005","journal-title":"J Invest Dermatol"},{"key":"2024111301173590200_CIT0018","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nm1162","article-title":"Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model","volume":"11","author":"Sano","year":"2005","journal-title":"Nat Med"},{"key":"2024111301173590200_CIT0019","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/ijms19010171","article-title":"A STAT3-centric view","volume":"19","author":"Calautti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2024111301173590200_CIT0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","article-title":"NF-\u03baB: an essential transcription factor in psoriasis","volume":"69","author":"Goldminz","year":"2013","journal-title":"J Dermatol Sci"},{"key":"2024111301173590200_CIT0021","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"2024111301173590200_CIT0022","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","article-title":"Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"159","author":"Schmitt","year":"2008","journal-title":"Br J Dermatol"},{"key":"2024111301173590200_CIT0023","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/tcrm.2006.2.4.389","article-title":"Infliximab (Remicade) in the treatment of psoriatic arthritis","volume":"2","author":"Mease","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"2024111301173590200_CIT0024","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/eji.202048857","article-title":"Mass cytometry analysis of blood immune cells from psoriasis patients on biological therapy","volume":"51","author":"Solberg","year":"2021","journal-title":"Eur J Immunol"},{"key":"2024111301173590200_CIT0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/cei.12335","article-title":"Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment","volume":"177","author":"Conigliaro","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2024111301173590200_CIT0026","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1365-2133.2012.10814.x","article-title":"Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis","volume":"166","author":"Luci","year":"2012","journal-title":"Br J Dermatol"},{"key":"2024111301173590200_CIT0027","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","article-title":"Relationship between CD107a expression and cytotoxic activity","volume":"254","author":"Aktas","year":"2009","journal-title":"Cell Immunol"},{"key":"2024111301173590200_CIT0028","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"2024111301173590200_CIT0029","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bjd.12067","article-title":"Natural killer cells and B lymphocytes in peripheral blood of patients with psoriasis","volume":"168","author":"Gambichler","year":"2013","journal-title":"Br J Dermatol"},{"key":"2024111301173590200_CIT0030","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2340\/00015555-1266","article-title":"Monitoring peripheral blood CD4(+) intracellular adenosine triphosphate concentration in patients with psoriasis treated with fumaric acid esters","volume":"92","author":"Gambichler","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"2024111301173590200_CIT0031","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jdv.15101","article-title":"Is the humoral immunity dispensable for the pathogenesis of psoriasis","volume":"33","author":"Thomas","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111301173590200_CIT0032","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaci.2015.08.027","article-title":"Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis","volume":"137","author":"Czarnowicki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024111301173590200_CIT0033","doi-asserted-by":"crossref","first-page":"204","DOI":"10.18176\/jiaci.0157","article-title":"Regulatory B cells and Allergy: uncovering the link","volume":"27","author":"Mota","year":"2017","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2024111301173590200_CIT0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41581-018-0074-7","article-title":"Effector and regulatory B cells in immune-mediated kidney disease","volume":"15","author":"Oleinika","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2024111301173590200_CIT0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12967-020-02289-w","article-title":"Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases","volume":"18","author":"Zhou","year":"2020","journal-title":"J Transl Med"},{"key":"2024111301173590200_CIT0036","doi-asserted-by":"crossref","first-page":"173ra23","DOI":"10.1126\/scitranslmed.3005407","article-title":"CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Flores-Borja","year":"2013","journal-title":"Sci Transl Med"},{"key":"2024111301173590200_CIT0037","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2340\/00015555-3069","article-title":"Aberrant B-cell subsets and immunoglobulin levels in patients with moderate-to-severe psoriasis","volume":"99","author":"Kahlert","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2024111301173590200_CIT0038","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2017.04.010","article-title":"IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFN\u03b3-producing T cells","volume":"184","author":"Mavropoulos","year":"2017","journal-title":"Clin Immunol"},{"key":"2024111301173590200_CIT0039","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol"},{"key":"2024111301173590200_CIT0040","doi-asserted-by":"crossref","first-page":"e20220201","DOI":"10.1084\/jem.20220201","article-title":"Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells","volume":"219","author":"Camponeschi","year":"2022","journal-title":"J Exp Med"},{"key":"2024111301173590200_CIT0041","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2017.05.012","article-title":"Regulatory B cells in rheumatoid arthritis: Alterations in patients receiving anti-TNF therapy","volume":"184","author":"Bank\u00f3","year":"2017","journal-title":"Clin Immunol"},{"key":"2024111301173590200_CIT0042","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/cimm.1996.0254","article-title":"The mechanism of interleukin 4-induced down-regulation of CD38 on human B cells","volume":"173","author":"Shubinsky","year":"1996","journal-title":"Cell Immunol"},{"key":"2024111301173590200_CIT0043","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/ard.2004.022731","article-title":"Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity","volume":"64","author":"Kawashima","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2024111301173590200_CIT0044","doi-asserted-by":"crossref","first-page":"e5374","DOI":"10.1590\/1414-431x20165374","article-title":"CD19+ B cell subsets in the peripheral blood and skin lesions of psoriasis patients and their correlations with disease severity","volume":"49","author":"Lu","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"2024111301173590200_CIT0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2133.2003.05319.x","article-title":"Circulating natural killer cells in psoriasis","volume":"149","author":"Cameron","year":"2003","journal-title":"Br J Dermatol"},{"key":"2024111301173590200_CIT0046","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: Implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024111301173590200_CIT0047","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1016\/j.ijcard.2013.07.127","article-title":"Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies","volume":"168","author":"Gu","year":"2013","journal-title":"Int J Cardiol"},{"key":"2024111301173590200_CIT0048","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bjd.16885","article-title":"Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT study, Norway","volume":"180","author":"Snekvik","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024111301173590200_CIT0049","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fimmu.2018.01234","article-title":"Potential immunological links between psoriasis and cardiovascular disease","volume":"9","author":"Sajja","year":"2018","journal-title":"Front Immunol"},{"key":"2024111301173590200_CIT0050","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.4049\/jimmunol.1402307","article-title":"Chronic psoriatic skin inflammation leads to increased monocyte adhesion and aggregation","volume":"195","author":"Golden","year":"2015","journal-title":"J Immunol"},{"key":"2024111301173590200_CIT0051","doi-asserted-by":"crossref","first-page":"e25595","DOI":"10.1371\/journal.pone.0025595","article-title":"Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes","volume":"6","author":"Passacquale","year":"2011","journal-title":"PLoS One"},{"key":"2024111301173590200_CIT0052","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/joim.12145","article-title":"Increased proatherogenic monocyte-platelet cross-talk in monocyte subpopulations of patients with stable coronary artery disease","volume":"275","author":"Czepluch","year":"2014","journal-title":"J Intern Med"},{"key":"2024111301173590200_CIT0053","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br J Dermatol"},{"key":"2024111301173590200_CIT0054","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2796.2012.02593.x","article-title":"Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study","volume":"273","author":"Ahlehoff","year":"2013","journal-title":"J Intern Med"},{"key":"2024111301173590200_CIT0055","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111301173590200_CIT0056","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"key":"2024111301173590200_CIT0057","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences","volume":"9","author":"Boehncke","year":"2018","journal-title":"Front Immunol"},{"key":"2024111301173590200_CIT0058","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"2024111301173590200_CIT0059","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.3390\/ijms20092255","article-title":"Lysosome alterations in the human epithelial cell line HaCaT and skin specimens: relevance to psoriasis","volume":"20","author":"Boche\u0144ska","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2024111301173590200_CIT0060","doi-asserted-by":"crossref","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"2024111301173590200_CIT0061","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/imm.12929","article-title":"The roles of resident, central and effector memory CD4 T-cells in protective immunity following infection or vaccination","volume":"154","author":"Gray","year":"2018","journal-title":"Immunology"},{"key":"2024111301173590200_CIT0062","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1189\/jlb.0404262","article-title":"CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines","volume":"77","author":"Sandoval-Montes","year":"2005","journal-title":"J Leukoc Biol"},{"key":"2024111301173590200_CIT0063","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cyto.a.22351","article-title":"From \u201ctruly na\u00efve\u201d to \u201cexhausted senescent\u201d T cells: when markers predict functionality","volume":"85","author":"Larbi","year":"2014","journal-title":"Cytometry A"},{"key":"2024111301173590200_CIT0064","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-2478(02)00223-7","article-title":"NKT cell subsets in infection and inflammation","volume":"85","author":"Chan","year":"2003","journal-title":"Immunol Lett"},{"key":"2024111301173590200_CIT0065","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ced.13795","article-title":"Effect of methotrexate monotherapy on T-cell subsets in the peripheral circulation in psoriasis","volume":"44","author":"Priyadarssini","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"2024111301173590200_CIT0066","doi-asserted-by":"crossref","first-page":"113081","DOI":"10.1016\/j.jim.2021.113081","article-title":"Effects of long-term cryopreservation of PBMC on recovery of B cell subpopulations","volume":"495","author":"Ticha","year":"2021","journal-title":"J Immunol Methods"},{"key":"2024111301173590200_CIT0067","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12865-022-00505-4","article-title":"Comprehensive evaluation of the effects of long-term cryopreservation on peripheral blood mononuclear cells using flow cytometry","volume":"23","author":"Li","year":"2022","journal-title":"BMC Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxae070\/59222920\/uxae070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/218\/3\/329\/60630343\/uxae070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/218\/3\/329\/60630343\/uxae070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:43:32Z","timestamp":1731498212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/218\/3\/329\/7731076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,9]]},"published-print":{"date-parts":[[2024,11,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxae070","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,9]]}}}